While specific Pfeiffer bacillus vaccines had been tried in treatment, the field was a comparatively new one so far as prevention was concerned. Many of the biological products companies had so-called influenza vaccines on the market for treatment purposes, and many of these contained Pfeiffer bacilli. A few preparations of pure strains of the bacilli were also available, but I was unable to find any records of their use for prophylaxis. Lacy (2) reported two cases of sinusitis treated with autogenous vaccines made from pure Pfeiffer strains—one patient improved rapidly and the other showed no change. Investigation of several of the other references on influenza vaccines showed that mixed vaccines had been used in each instance. The work of Flexner and Wolstein (3, 4 and 5) indicated that active immunizing substances could be prepared from the Pfeiffer bacillus, although they worked with serum instead of vaccines. They prepared an anti-influenza-meningitis serum by immunizing goats and horses. These sera cured monkeys of experimentally produced influenzal meningitis. The sera showed agglutinins and bacteriotropins for Pfeiffer bacilli, as well as positive fixation tests in dilutions of 1 in 100, but they contained no lysins. The serum was offered for intradural use in treating influenzal meningitis, but was found to have no value when used in human cases. The first references which we have found on the use of pure Pfeiffer bacillus vaccines for the prevention of epidemic influenza were those of Leary (6), (7), and of Rosenau (8). Shortly after the appearance of the first influenza cases in Boston, Leary used a vaccine prepared from several strains of Pfeiffer bacilli both for the treatment of influenza and for its prevention. The vaccine for the latter purpose was given to medical students and nurses, and the first results were apparently very encouraging. Continued use has not been convincing. Barnes (9) reported an attempt to protect the employees and patients of an institution near Woonsocket. On October 9 a case of influenza developed in the female ward, and was followed five days later by another. On October 22 the disease appeared in the male ward, and the same day 172 employees and patients were given their first inoculation with Leary’s vaccine. Doses of 400, 800 and 1,200 million bacilli were given at 24–hour intervals. All persons who had developed influenza before the three doses had been completed were excluded from the computation of the disease incidence, which was found to be 20 per cent. both among vaccinated and unvaccinated individuals. The mortality rate was 16 per cent. for the 25 cases among the vaccinated, and 15.8 per cent. among 57 unvaccinated patients. The result failed to show any protective qualities for the vaccine.